Apollomics Inc. (NASDAQ:APLM – Get Free Report)’s share price traded down 0.6% on Tuesday. The stock traded as low as $19.88 and last traded at $19.7810. Approximately 91,520 shares were traded during mid-day trading, The stock had previously closed at $19.90.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Wall Street Zen raised Apollomics to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings raised shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Report on APLM
Apollomics Price Performance
The company’s 50-day moving average price is $23.42 and its 200 day moving average price is $19.03.
Insiders Place Their Bets
In related news, COO Yi-Kuei Chen acquired 20,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $15.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the chief operating officer directly owned 121,248 shares of the company’s stock, valued at approximately $1,818,720. This trade represents a 19.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Hung-Wen Chen bought 266,667 shares of the company’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. Following the completion of the transaction, the chief executive officer directly owned 1,029,695 shares of the company’s stock, valued at approximately $15,445,425. The trade was a 34.95% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 583,334 shares of company stock valued at $8,250,510.
Hedge Funds Weigh In On Apollomics
An institutional investor recently bought a new position in Apollomics stock. Citadel Advisors LLC purchased a new position in Apollomics Inc. (NASDAQ:APLM – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,664 shares of the company’s stock, valued at approximately $224,000. Citadel Advisors LLC owned approximately 0.48% of Apollomics as of its most recent SEC filing. Institutional investors and hedge funds own 19.13% of the company’s stock.
Apollomics Company Profile
Apollomics, Inc (NASDAQ:APLM) is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Its research programs are centered on immuno-oncology and precision oncology, with the goal of combining therapies that activate the immune system with treatments designed to target specific characteristics of tumors.
The company’s pipeline includes investigational small-molecule and antibody-based therapies intended for use across a range of solid tumors and blood cancers.
See Also
- Five stocks we like better than Apollomics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
